HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Employees

1,811

Sector

Pharmaceuticals

Calendar

08-07 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
10/07/25	231.00 p	-1.70%	9,802
09/07/25	235.00 p	+1.29%	15,219
08/07/25	232.00 p	+2.65%	14,282
07/07/25	226.00 p	-1.31%	2,792
04/07/25	229.00 p	-0.43%	8,750

Delayed Quote London S.E., July 10, 2025 at 04:35 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.133USD

Average target price

5.008USD

Spread / Average Target

+59.83%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 16:35:18 10/07/2025 BST			5-day change	1st Jan Change
231.00 ^GBX	-1.70%		+4.52%	-1.70%

06-30	Hutchmed Gets China Nod for Combination of Two Drugs to Treat Non-Small Cell Lung Cancer	MT
06-30	Hutchmed (China) Gets Chinese Regulatory Nod for Lung Cancer Therapy	MT

Capitalization	2.68B 2.29B 2.13B 1.97B 3.66B 230B 4.07B 25.46B 9.73B 108B 10.05B 9.84B 392B	P/E ratio 2025 *	8.3x	P/E ratio 2026 *	37.4x
Enterprise value	2.31B 1.97B 1.84B 1.7B 3.15B 198B 3.5B 21.91B 8.37B 92.61B 8.65B 8.47B 337B	EV / Sales 2025 *	3.33x	EV / Sales 2026 *	2.68x
Free-Float	57.51%	Yield 2025 *	-	Yield 2026 *	-

Hutchmed Gets China Nod for Combination of Two Drugs to Treat Non-Small Cell Lung Cancer	06-30	MT
Hutchmed (China) Gets Chinese Regulatory Nod for Lung Cancer Therapy	06-30	MT
Hutchmed New Drug Application for Lung Cancer Combination Treatment Approved in China	06-30	MT
Hutchmed Limited Announces China Approval for Orpathys®? in Combination with Tagrisso®? for the Treatment of Lung Cancer	06-30	CI
HUTCHMED Limited Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:40 PM	06-09
Hutchmed, Innovent's Kidney Cancer Combo Drug Accepted for Review in China	06-05	MT
Hutchmed Limited and Innovent Biologics, Inc. Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma	06-05	CI
Hutchmed China kidney cancer therapy accepted for review in China	06-05	AN
Hutchmed, Innovent Biologics Say China Accepts Kidney Cancer Drug Combo Application for Review	06-05	MT
Chinese Regulator to Review Hutchmed's New Drug Application for Renal Cell Carcinoma Treatment Combo	06-05	MT
Hutchmed, Innovent Kidney Cancer Drug Combo Accepted for Review in China; Shares Up 5%	06-05	MT
HUTCHMED Limited and Innovent Biologics, Inc. Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma	06-05	CI
HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab	06-05	RE

BofA Securities Adjusts Price Target on HUTCHMED (China) to $27 From $26, Maintains Buy Rating	02-11	MT
BofA Securities Cuts Price Target on HUTCHMED to $26 From $30, Maintains Buy Rating	01-07	MT
Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target	12-19	MT
Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20	24/11/23	MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating	10/11/23	MT

HUTCHMED (China) Limited Share Price

Equities

HCM

KYG4672N1198

Pharmaceuticals

Valuation: HUTCHMED (China) Limited

Chart: HUTCHMED (China) Limited

Latest news: HUTCHMED (China) Limited

Last Transcript: HUTCHMED (China) Limited

Analysts' recommendations: HUTCHMED (China) Limited

Press Releases: HUTCHMED (China) Limited

News in other languages: HUTCHMED (China) Limited

Quotes and Performance

Course Extremes

Managers and Directors: HUTCHMED (China) Limited

ETFs: HUTCHMED (China) Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025	04-24	AQ
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China	04-22	AQ
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK for the Treatment of Relapsed or Refractory Follicular Lymphoma	03-24	AQ
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025	03-20	AQ
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China	03-06	AQ

Trump, Acte II	01-02
En Direct des Marchés : BYD prend des parts de marché, Apple fait des prix et sinon pas grand chose	01-02
Bolsa de Madrid: Mercados un poco confusos	11/03/22
EN DIRECT DES MARCHES : Stellantis, Wendel, Soitec, Umanis, Tod's, Deutsche Telekom, Oracle, Rivian...	11/03/22
MÄRKTE ASIEN/Schwächer - Schlussrally hievt Schanghai ins Plus	11/03/22

1 day	-1.70%
1 week	+4.52%
Current month	+1.76%
1 month	-2.94%
3 months	+22.22%
6 months	-9.41%
Current year	-1.70%

Manager	Title	Age	Since
Wei Guo Su CEO	Chief Executive Officer	67	03/03/2022
Chig Fung Cheng DFI	Director of Finance/CFO	58	30/06/2008
Michael Shi CTO	Chief Tech/Sci/R&D Officer	60	31/12/2021

Director	Title	Age	Since
Edith Shih BRD	Director/Board Member	73	31/12/2005
Chig Fung Cheng BRD	Director/Board Member	58	31/12/2010
Wei Guo Su BRD	Director/Board Member	67	26/03/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
HUTCHMED (CHINA) LIMITED	-1.70%	+4.52%	-13.16%	-8.33%	2.73B
ELI LILLY AND COMPANY	+0.47%	+1.46%	-15.21%	+139.25%	706B
JOHNSON & JOHNSON	+0.90%	+1.37%	+7.24%	-11.55%	376B
ABBVIE INC.	+2.30%	+2.23%	+16.04%	+27.58%	337B
NOVO NORDISK A/S	+2.82%	+3.18%	-52.84%	+14.03%	309B
ROCHE HOLDING AG	+1.15%	+1.11%	+7.52%	-18.30%	262B
NOVARTIS AG	+1.70%	+0.79%	+2.18%	+19.88%	240B
ASTRAZENECA PLC	+2.55%	+2.27%	-11.03%	-3.78%	218B
MERCK & CO., INC.	+0.37%	+1.98%	-33.34%	-9.44%	210B
AMGEN INC.	+1.30%	+1.19%	-4.92%	+20.88%	159B
Average	+0.85%	+1.11%	-9.75%	+17.02%	282.04B
Weighted average by Cap.	+0.98%	+0.44%	-9.46%	+38.33%

	2025 *	2026 *
Net sales	693M 593M 552M 511M 947M 59.43B 1.05B 6.59B 2.52B 27.84B 2.6B 2.55B 101B	827M 706M 658M 609M 1.13B 70.84B 1.25B 7.85B 3B 33.18B 3.1B 3.04B 121B
Net income	333M 284M 265M 245M 454M 28.51B 505M 3.16B 1.21B 13.36B 1.25B 1.22B 48.63B	103M 88.19M 82.2M 75.98M 141M 8.84B 157M 980M 375M 4.14B 387M 379M 15.09B
Net Debt	-373M -319M -297M -275M -510M -31.99B -566M -3.55B -1.36B -14.99B -1.4B -1.37B -54.57B	-469M -400M -373M -345M -640M -40.15B -711M -4.45B -1.7B -18.81B -1.76B -1.72B -68.49B

1 week	226	240
1 month	216	265
Current year	185.5	270
1 year	185.5	336
3 years	130	353
5 years	130	656
10 years	130	656